When comparing IDH1 and IDH2‐mutated AML, we found no significant difference in the magnitude or rate of blast reduction (median log10 fold reduction and log10/day), or OS, consistent with Middeke et al. The gene discussed is IDH1; the disease is acute myeloid leukemia.